Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01951326 |
Recruitment Status :
Completed
First Posted : September 26, 2013
Results First Posted : May 1, 2020
Last Update Posted : December 8, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment |
Condition |
Crohn's Disease |
Interventions |
Drug: RHB-104 Drug: Placebo |
Enrollment | 331 |
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | RHB-104 | Placebo |
---|---|---|
Arm/Group Description |
5 RHB-104 capsules administered orally BID RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine |
5 placebo capsules administered orally BID Placebo: 5 placebo capsules administered orally BID |
Period Title: Overall Study | ||
Started | 166 | 165 |
Completed | 87 | 87 |
Not Completed | 79 | 78 |
Arm/Group Title | RHB-104 | Placebo | Total | |
---|---|---|---|---|
Arm/Group Description |
5 RHB-104 capsules administered orally BID RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine |
5 placebo capsules administered orally BID Placebo: 5 placebo capsules administered orally BID |
Total of all reporting groups | |
Overall Number of Baseline Participants | 166 | 165 | 331 | |
Baseline Analysis Population Description |
[Not Specified]
|
|||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 166 participants | 165 participants | 331 participants | |
39.0 (12.51) | 39.3 (12.56) | 39.1 (12.52) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 166 participants | 165 participants | 331 participants | |
Female |
75 45.2%
|
67 40.6%
|
142 42.9%
|
|
Male |
91 54.8%
|
98 59.4%
|
189 57.1%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 166 participants | 165 participants | 331 participants | |
American Indian or Alaska Native |
0 0.0%
|
1 0.6%
|
1 0.3%
|
|
Asian |
0 0.0%
|
1 0.6%
|
1 0.3%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
8 4.8%
|
12 7.3%
|
20 6.0%
|
|
White |
156 94.0%
|
150 90.9%
|
306 92.4%
|
|
More than one race |
2 1.2%
|
1 0.6%
|
3 0.9%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
Number Analyzed | 166 participants | 165 participants | 331 participants |
Europe | 47 | 50 | 97 | |
Israel | 18 | 20 | 38 | |
Southeast Asia | 9 | 12 | 21 | |
North America | 92 | 83 | 175 | |
Baseline Crohn's Disease Activity Index (CDAI) score
[1] Mean (Standard Deviation) Unit of measure: Units on a scale |
||||
Number Analyzed | 166 participants | 165 participants | 331 participants | |
297.77 (57.023) | 293.44 (53.184) | 295.61 (55.102) | ||
[1]
Measure Description:
Generally, CDAI scores can range from 0 to ~600. (in this protocol up to 450) CDAI scores of 150-219 describe mildly active disease, while scores of 220-450 describe moderately active disease and scores above 450 describe severe disease. |
||||
Anti-TNF Use at Baseline
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 166 participants | 165 participants | 331 participants | |
37 22.3%
|
41 24.8%
|
78 23.6%
|
Name/Title: | Reza Fathi, Senior VP Research and Development |
Organization: | RedHill Biopharma |
Phone: | 972-(0)3-541-3131 |
EMail: | reza@redhillbio.com |
Responsible Party: | RedHill Biopharma Limited |
ClinicalTrials.gov Identifier: | NCT01951326 |
Other Study ID Numbers: |
RHB-104-01 |
First Submitted: | September 19, 2013 |
First Posted: | September 26, 2013 |
Results First Submitted: | March 29, 2020 |
Results First Posted: | May 1, 2020 |
Last Update Posted: | December 8, 2020 |